Zelgen Biopharmaceuticals

Company snapshot

Suzhou Zelgen Biopharmaceuticals is a biotech organization headquartered in CN. Primary therapeutic focus areas include ALK-positive Non-small Cell Lung Cancer, Biliary Tract Carcinoma, Advanced Solid Tumor. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2), phase 1 (1).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zelgen Biopharmaceuticals. Not investment advice.

• What is Zelgen Biopharmaceuticals?

  Suzhou Zelgen Biopharmaceuticals is a biotech organization headquartered in CN. Primary therapeutic focus areas include ALK-positive Non-small Cell Lung Cancer, Biliary Tract Carcinoma, Advanced Solid Tumor. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 pat

• Is Zelgen Biopharmaceuticals publicly traded?

  Zelgen Biopharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Zelgen Biopharmaceuticals develop or market?

  We link 7 drug profile(s) where Zelgen Biopharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/suzhou-zelgen-biopharmaceuticals-co-ltd#company-drugs.

• What are the latest developments for Zelgen Biopharmaceuticals?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zelgen Biopharmaceuticals focus on?

  Zelgen Biopharmaceuticals focuses on ALK-positive Non-small Cell Lung Cancer, Biliary Tract Carcinoma, Advanced Solid Tumor based on our analysis of their pipeline programs and drug development activities.